Sarah Blagden

Sarah Blagden is an associate professor of experimental cancer therapeutics at the University of Oxford in the Department of Oncology at Oxford. Her research is investigating post-transcriptional mechanisms for cancer behavior and novel cancer therapeutics for people with advanced malignancies.[1][2][3]

Sarah Blagden
EducationMedical Degree (MBBS), PhD (as CRUK Clinical Fellow)
OccupationAssociate Professor of Experimental Cancer Therapeutics
Years active2015 - present
Organization(s)University of Oxford, Department of Oncology

Education

Sarah Blagden received a medical degree (MBBS) at Charing Cross and Westminster Medical School, University of London in 1994.[4]

In 2004 she received a PhD (as CRUK Clinical Fellow) at Cambridge University[4]

Career

After Blagden completed her medical training and subsequent specialist training in Medical Oncology at Addenbrooke's Hospital in Cambridge and the Royal Mardsden Hospital she went on to hold a Clinical Fellowship at the Institute of Cancer Research's Drug Development Unit.[1] She was appointed to Senior Lecturer and Honorary Consultant at the Imperial College in 2006 and became a Director of Imperial's Early Cancer Trials Unit and was able to established her own laboratory for studying the dysregulation of mRNA translation in cancer.[1]

Blagden was also a chief/Principal investigator for a number of national and international clinical studies.[1] She is a Researcher and Associate Professor of Experimental Cancer therapeutics at the University of Oxford in the department of oncology[1][2]

She was a cofounder of the LARP Society, a scientific society dedicated to the study of La-related family of proteins.[5] She serves on the Editorial Board of the British Journal of Cancer.[6]

Awards
  • CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University[1]
  • CRUK clinical Fellow PhD in 2004 at Cambridge University.[4]
  • Fellowship of Royal College Physicians in 2010[4]

References
  1. "Sarah Blagden". www.oncology.ox.ac.uk. Retrieved 2021-03-01.
  2. "Professor Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics — University of Oxford, Medical Sciences Division". www.medsci.ox.ac.uk. Retrieved 2021-03-01.
  3. ORCID. "Sarah Blagden (0000-0001-8783-3491)". orcid.org. Retrieved 2021-03-01.
  4. "Home - Dr Sarah Blagden". www.imperial.ac.uk. Retrieved 2021-03-01.
  5. Blagden, Sarah P.; Bayfield, Mark; Bousquet-Antonelli, Cecile (2021-02-01). "A decade of LARP society". RNA Biology. 18 (2): 157–158. doi:10.1080/15476286.2020.1755505. ISSN 1547-6286. PMC 7928030. PMID 33651971.
  6. "Editorial Board | British Journal of Cancer". www.nature.com. Retrieved 2022-07-11.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.